Editorial: In vitro mechanistic evaluation of nucleic acid polymers: A cautionary tale

[Display omitted] The LNA-modified NAP ALG-10133 is inactive against HBV infection in humans compared with the potent activity of non-LNA-modified NAPs such as REP 2139. This inactivity illustrates the negative impact LNA has on the antiviral activity of NAPs and highlights critical artifacts in tra...

Full description

Saved in:
Bibliographic Details
Published inMolecular therapy. Nucleic acids Vol. 28; pp. 168 - 174
Main Author Vaillant, Andrew
Format Journal Article
LanguageEnglish
Published United States Elsevier Inc 14.06.2022
American Society of Gene & Cell Therapy
Elsevier
Subjects
hepatitis B
mechanism of action
nucleic acid polymer
oligonucleotide
transfection artifacts
transfection artifacts
mechanism of action
nucleic acid polymer
hepatitis B
oligonucleotide
Online AccessGet full text

Cover

More Information
Summary:[Display omitted] The LNA-modified NAP ALG-10133 is inactive against HBV infection in humans compared with the potent activity of non-LNA-modified NAPs such as REP 2139. This inactivity illustrates the negative impact LNA has on the antiviral activity of NAPs and highlights critical artifacts in transfection-based systems used for their in vitro evaluation.
Bibliography:SourceType-Other Sources-1
content type line 63
ObjectType-Editorial-2
ObjectType-Commentary-1
ISSN:2162-2531
2162-2531
DOI:10.1016/j.omtn.2022.03.002